Ongoing research into AI agent framework security identified an exploit chain in AutoGen Studio (AutoGen’s open-source prototyping user interface) that allows untrusted web content rendered by a ...

Spread the love“`html For anyone running an online store, a smoothly functioning shopping cart is crucial. However, many WooCommerce users find themselves facing a frustrating issue: the WooCommerce ...

This was an easy pick for Utah. The Jazz wanted Darryn Peterson, the Kansas guard, and took him at No. 2 on Tuesday night.

Brighton fans have been getting in touch with BBC Radio Sussex as the Seagulls celebrate their 125-year anniversary during ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

All the latest reaction to Scotland's World Cup win and latest as Germany and the Netherlands play their first games.

Trials of the British Army’s Ajax armoured vehicles are set to resume, despite major delays amid concern for soldiers’ safety. Minister for Defence Readiness and Industry Luke Pollard announced in ...

Trials of the British Army's Ajax armoured vehicle will be "proceeding cautiously" after they were halted last year, a defence minister has said. A decision was made to stop using the Ajax after ...

Eli Lilly LLY-1.21%decrease; down pointing triangle continued its recent buying spree, agreeing to pay up to $2.3 billion for Ajax Therapeutics in a deal that bolsters the drugmaker’s blood-cancer ...

Eli Lilly (LLY) has agreed to acquire biopharmaceutical company Ajax Therapeutics for up to $2.3B in cash, inclusive of an upfront payment and subsequent payments upon the achievement of certain ...

Eli Lilly said on Monday it would buy privately held cancer drug developer Ajax Therapeutics for up to $2.3 billion in cash, as the U.S. drugmaker looks to expand its oncology pipeline. Lilly has been ...

Eli Lilly & Co. agreed to buy closely held Ajax Therapeutics Inc. for as much as $2.3 billion in cash, part of its effort to build out a portfolio of breakthrough cancer therapies. Ajax’s lead ...